PRECLINICAL AND CLINICAL CHARACTERIZATION OF CENERIMOD, A POTENT, SELECTIVE, AND ORALLY ACTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 MODULATOR IN SLE

1Daniel S Strasser, 1Estelle Gerossier, 1Virginie Sippel, 2Ursula Grieder, 2Andrea Kleininger-Gräffitsch, 1Gabriela Gotsch, 1Hervé Faivre, 1Paulina Kulig, 1Marcel Keller, 2Sylvie Froidevaux, 2Marten Trendelenburg. 1Mark Murphy, 1Marianne Martinic, 1Idorsia Pharmaceuticals Ltd, Allschwil, 2Division of Internal Medicine and Clinical Immunology, University Hospital Basel, Basel, Switzerland

Methods Lymphocytes from patients with SLE and healthy subjects were assessed for cenerimod-induced S1P1 receptor internalization. Efficacy of cenerimod was evaluated in the MRL/lpr lupus mouse model. In a 12-week phase 2 clinical trial in SLE subjects treated with multiple doses of cenerimod (NCT02472795), lymphocyte subsets and inflammatory biomarkers were characterized.

Results Cenerimod was potent and efficacious at inducing S1P1 receptor internalization in T and B lymphocytes with an EC50 of ~15 nM in both healthy subjects and patients with SLE. In lupus-like MRL/lpr mice treated with cenerimod, circulating T and B lymphocytes were reduced, which resulted in reduced immune infiltrates into tissue, reduced autoantibody production and inflammation, preserved organ function, and increased survival. In SLE subjects treated with cenerimod for 12 weeks, a dose-dependent reduction of circulating T cells (95%), B cells (90%), and antibody-secreting cells (85%) was evident. Furthermore, a reduction in anti-dsDNA antibodies and IFN-α, two key inflammatory molecules, was observed.

Conclusion Cenerimod was potent and efficacious in reducing S1P1 receptor surface expression on lymphocytes, resulting in reduced circulating T and B lymphocyte populations, including antibody-secreting cells, and a decrease in inflammatory biomarkers in SLE subjects. Furthermore, cenerimod significantly ameliorated systemic and organ-specific autoimmunity in a mouse model of SLE. These results warranted the further investigation of the clinical efficacy and safety of cenerimod in the ongoing phase 2b clinical trial (NCT03742037).

Acknowledgements This research was funded by Idorsia Pharmaceuticals Ltd.

DIFFICULTIES IN MANAGING A PATIENT WITH MULTI-ORGAN DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS AND A HIGH RISK OF THROMBOTIC EVENTS IN ANTIPHOSPHOLIPID SYNDROME (CASE REPORT)

1,2Fariza Cheldieva, 1Tatiana Reshetnyak, 1Anastasia Shumilova, 1Natalia Seredavkina, 1Maria Cherkasova, 1Tatiana Lisitnya, 1Anastasia Borisova, 1Alexander Lila. 1Federal State Budgetary Scientific Institution ‘Research Institute of Rheumatology named after V.A. Nasonova’, Moscow; 2Federal State Budgetary Educational Institution of Further Professional Education ‘Russian Medical Academy of Continuous Professional Education’ of the Ministry of Healthcare of the Russian Federation, Rheumatology Academic Dept., Moscow; 3Moscow Research Institute of Psychiatry, Seizky NMRC PN MoH, Moscow, Russian Federation

Methods All patients with primary and secondary APS attending rheumatology clinics from January 2017 to May 2019 at Hamad General Hospital were identified and medical records were retrospectively reviewed.

Results 131 patients with APS who fulfilled revised Sapporo APS classification criteria were included- 116 women (88.5%) and 15 men (11.5%). 79 patients (60.3%) had primary and 52 patients (39.7%) had secondary APS. 41 patients (31.3%) had thrombotic event only, 64 patients (48.9%) had pregnancy morbidity only, and 26 patients (19.8%) had both thrombosis as well as pregnancy morbidity. 7 patients (5.4%) had arterial thrombosis only, 48 patients (36.6%) had venous thrombosis only and 12 patients (9.1%) had both arterial and venous thrombosis. 103 (78.6%) patients had pregnancy morbidity out of the 116 female patients. Early fetal loss was the commonest pregnancy morbidity seen in 73 patients (70.9%), followed by late fetal loss in 57 patients (55.3%).

48 patients (36.6%) had aCL IgG positive and 15 patients (11.5%) had aCL IgM positive, either one was positive in 54 patients (41.2%). 42 patients (32.1%) had B2GP IgG positive and 19 patients (14.5%) had B2GP IgM positive, either one was positive in 53 patients (40.7%). LA was positive in 121 patients (92.4%). There were 71 patients (54.2%) with single positive aPL test, 21 patients (16%) with double positive and 37 patients (28.2%) with triple positive aPL test results. LA was the most common single positive aPL test, seen in 65 patients (50.3%).

Conclusion The clinical manifestation and immunological characteristics of patients with APS in Qatar are diverse. Our cohort has much higher prevalence of LA positivity compared to other cohorts around the world. We also have a higher incidence of pregnancy morbidities.

Acknowledgements Study funded by Medical research center at Hamad Medical Corporation.

ANTIPHOSPHOLIPID SYNDROME IN QATAR: EPIDEMIOLOGICAL, CLINICAL, AND IMMUNOLOGICAL CHARACTERISTICS

Nabeel Abdulb, Omar Alsaed, Fiaz Alam, Rawan Saleh, Abdulrazakh Poli, Abdellah Sami Eman Elsayed, Han Abdulal, Samar Al Emadi. Rheumatology Division, Hamad Medical Corporation, Doha, Qatar

Purpose The aim of this study is to analyze epidemiological, clinical, and immunologic characteristics of primary and secondary antiphospholipid syndrome (APS) cases in Qatar.